Coapt
Coapt develops FDA-cleared myoelectric pattern recognition software and hardware that translate muscle signals into intuitive prosthetic arm and hand movements, sold to prosthetists, clinics, and OEM partners globally. The Chicago-based firm was acquired by Hanger, Inc. in 2025.
- Company typePrivate
- Founded2012
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Coapt does
Coapt is a Chicago-based medical device company founded in 2012 that develops myoelectric pattern recognition technology for upper limb prosthetics. Its flagship product, Complete Control Gen2, is an FDA Class II-cleared controller kit that uses machine learning algorithms to decode electromyographic (EMG) signals from residual limb muscles in real time and translate user intent into intuitive prosthetic arm and hand movements. The system is device-agnostic, compatible with 400-450+ upper-limb prosthesis configurations from manufacturers including Ottobock, Össur, TASKA, bebionic, Vincent, and Esper, and is paired with the Control Coach AI companion and the Control Companion mobile app (iOS/Android) for in-clinic setup and on-the-go calibration. Coapt sells primarily through prosthetic clinics and licensed prosthetists, licenses its technology to OEMs for integration, and supplements revenue with federally funded research grants; the firm operates a Boston-area R&D subsidiary, Liberating Technologies, Inc.
The company's go-to-market spans clinical, OEM, and government channels: direct sales to prosthetists via a 1-844 contact line, OEM integration partnerships across the major upper-limb manufacturers, and DoD-funded research programs (notably a $2.3M RESTORE grant in 2020 for VR-based phantom limb pain therapy). Products are commercially available in the United States, Canada, Australia, New Zealand, and across much of Europe. In January 2025, Coapt secured HCPCS Code L6700 — the first dedicated reimbursement code for advanced pattern-recognition prosthetic control — and in February 2025 announced an agreement to be acquired by Hanger, Inc., the largest U.S. orthotic and prosthetic provider with 900+ clinic locations; the transaction was expected to close in Q1 2025 and would substantially broaden clinical access to Coapt's technology.
Coapt firmographics
Firmographics- Name
- Coapt
- Legal name
- Coapt, LLC
- Website
- https://coaptengineering.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Coapt develops FDA-cleared myoelectric pattern recognition software and hardware that translate muscle signals into intuitive prosthetic arm and hand movements, sold to prosthetists, clinics, and OEM partners globally. The Chicago-based firm was acquired by Hanger, Inc. in 2025.
- Ownership category
- akta.pro rank
Coapt industry classification
Industry- Product category
- Upper-Limb Prosthetic Control Systems
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems) (HLAHAEAH)
- akta.pro secondary industry
- Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets) (HLAHAMAD)
Keywords
Where Coapt is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Coapt business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Complete Control Gen2 System Sales: Coapt sells the Complete Control Gen2 hardware system — an add-on intent decoder controller kit — to prosthetists and clinics. The system is billed under HCPCS code L6700 (effective April 1, 2025) for Medicare and other health insurance reimbursement. CMS payment is made on a purchase basis.
- Licensing & Integration Partnerships: Coapt licenses its pattern recognition technology to prosthetic device manufacturers, enabling integration of its intent decoding system into their prosthetic arms and hands. The company works with product manufacturers to incorporate its technology into myoelectric prostheses.
- Mobile Application (Control Companion): The Control Companion mobile app provides additional functionality for users and clinicians, available on iOS and Android app stores. The app includes training tools, games, and Control Coach AI integration.
- Government Research Grants: Coapt receives federally funded research grants, including a $2.3M Department of Defense RESTORE grant for VR-based phantom limb pain therapy development. LTI has received over 45 federally funded research awards totaling over $24.9M. These are non-dilutive funding sources.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Complete Control Gen2 System (L6700) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Coapt product offering
Product offeringCore offering
Coapt designs, manufactures, and sells the Complete Control Gen2 system, an FDA Class II-cleared add-on controller kit that uses machine-learning pattern recognition to decode myoelectric (EMG) signals from a user's residual limb muscles and translate them into intuitive movements of a powered upper-limb prosthesis. The kit is paired with the Control Coach AI companion and the Control Companion iOS/Android mobile app, is device-agnostic across 400+ upper-limb prosthesis configurations, and is sold primarily to certified prosthetists and O&P clinics while also being licensed to prosthetic component manufacturers.
Product overview
Coapt offers a unified product ecosystem centered on its Complete Control Gen2 pattern recognition technology for upper limb prosthetic control. The core offering is the Complete Control system—an FDA Class II-cleared myoelectric, machine learning prosthesis control system that decodes user intent from muscle signals. This integrates with the Control Coach AI companion for intelligent calibration guidance and the Control Companion mobile app for on-the-go refinement. Coapt's technology is device-agnostic, compatible with over 400 upper-limb prosthesis configurations from manufacturers including Ottobock, Össur, TASKA, and others. The company operates through its main Chicago headquarters and research subsidiary Liberating Technologies, Inc. in Boston, and was acquired by Hanger, Inc. in 2025.
Differentiator
Problem solved
Functional benefit
Brands
- Complete Control Gen2: Best-in-class pattern recognition intent decoding technology for upper limb prosthesis wearers. An add-on controller kit offering unprecedented intuitiveness for patient lifestyles.
- Control Coach
- Control Companion
Products and services
- Complete Control Gen2 FDA Class II-cleared, add-on pattern-recognition controller kit that decodes myoelectric (EMG) signals from residual limb muscles using machine-learning algorithms and translates user intent into intuitive movements of a powered upper-limb prosthesis. Device-agnostic across 400+ upper-limb prosthesis configurations. Sold primarily to certified prosthetists and O&P clinics and reimbursed under HCPCS L6700.
- Control Coach AI Companion AI-powered companion embedded in the Gen2 system that analyzes how users personalize their intent decoding, provides 5-star quality ratings across data sufficiency, specificity, repeatability, robustness, and intensity, and delivers corrective suggestions to optimize prosthetic control. Designed for both clinicians and end users.
- Control Companion Mobile App iOS and Android mobile app distributed via the App Store (id 1578333990) and Google Play store that serves as the central hub for clinicians and end users for in-clinic setup, calibration controls, Adaptive Advance controls, save/restore of calibrations, training tools and games, and Control Coach AI integration.
- ControlSeal Electrode Dome Proprietary electrode dome accessory for the Complete Control Gen2 system designed to maintain consistent skin contact for reliable myoelectric signal capture during calibration and daily use.
- Complete Control Room v2 Application Desktop clinician application used to configure and manage Coapt Complete Control prosthetic control systems, distributed under an End User License Agreement.
Quantifiable outcome
- 400+ upper-limb prosthesis combinations supported
- +2 more outcomes
Companies that use Coapt
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles3 records
Coapt technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Coapt partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Hanger, Inc.flagshipHanger, Inc. — a leading provider of orthotic and prosthetic patient care services with 900+ Hanger Clinic locations nationwide — announced an agreement to acquire Coapt. Hanger's CEO Pete Stoy stated the technology is a natural complement to Hanger's focus on bringing innovation to patient care. The acquisition was expected to close in Q1 2025. Hanger's manufacturing capability and clinic footprint is expected to strengthen Coapt's products and broaden their use.
- WillowWood Global LLCcoreCoapt collaborated with WillowWood Global to release the Alpha Control Liner System — the first prosthetic liner with embedded electronics. The liner captures and conditions muscle contraction signals and communicates seamlessly with Coapt's Complete Control myoelectric pattern recognition system. The partnership was described as combining revolutionary liner technology with best-in-class myoelectric technology to define the new gold standard for prosthesis control. The collaboration was funded in part by a Department of Defense clinical trial.
- Liberating Technologies, Inc. (LTI)coreCoapt acquired Liberating Technologies, a prosthetics developer based in Holliston, MA (previously owned by College Park Industries). LTI serves as Coapt's research and development subsidiary, headquartered in the Boston area. Todd Farrell, Ph.D. was named CEO of LTI in June 2023. LTI has secured over 45 federally funded research awards totaling over $24.9M.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Coapt competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Coapt social profiles
Digital presenceCoapt compliance and trust
Trust signalCompliance2 records
Coapt financial estimates
Financial estimateRevenue estimate
Valuation estimate
Coapt leadership team
Management profileNumber of profiles
Profiles3 records
Coapt subsidiaries and ownership
Company hierarchySubsidiaries1 record
Coapt funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Coapt M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Coapt
What does Coapt do?
Coapt designs, manufactures, and sells the Complete Control Gen2 system, an FDA Class II-cleared add-on controller kit that uses machine-learning pattern recognition to decode myoelectric (EMG) signals from a user's residual limb muscles and translate them into intuitive movements of a powered upper-limb prosthesis. The kit is paired with the Control Coach AI companion and the Control Companion iOS/Android mobile app, is device-agnostic across 400+ upper-limb prosthesis configurations, and is sold primarily to certified prosthetists and O&P clinics while also being licensed to prosthetic component manufacturers.
Is Coapt a public or private company?
Coapt is a private company. It is classified as corporate owned and is currently acquired.
When was Coapt founded?
Coapt was founded in 2012. It employs 11 to 50 people.
Where is Coapt based?
Coapt is headquartered in Chicago, United States, in the North America region.
How does Coapt make money?
Four revenue lines are on record. Complete Control Gen2 System Sales are the primary driver. The others are licensing & Integration Partnerships, mobile Application (Control Companion) and government Research Grants.
Does Coapt have an API?
No public API is recorded for Coapt.
What industry is Coapt in?
Coapt's product category is Upper-Limb Prosthetic Control Systems. Its primary akta.pro industry code is HLAHAEAH, Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems), with a secondary code of HLAHAMAD, Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets). Its NAICS code is 339113 and its SIC code is 3842.